<DOC>
	<DOCNO>NCT02873936</DOCNO>
	<brief_summary>The primary objective study evaluate effect filgotinib versus placebo adult active rheumatoid arthritis ( RA ) inadequate response biologic disease-modifying anti-rheumatic drug ( ) ( DMARDs ) treatment .</brief_summary>
	<brief_title>Filgotinib Versus Placebo Adults With Active Rheumatoid Arthritis ( RA ) Who Have Inadequate Response Biologic Disease-modifying Anti-rheumatic Drug ( ) ( DMARDs ) Treatment</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Have diagnosis RA ( 2010 ACR/EULAR criterion RA ) , ACR functional class IIII . Have ≥ 6 swollen joint ( swollen joint count base 66 joint ( SJC66 ) ) ≥6 tender joint ( tender joint count base 68 joint ( TJC68 ) ) screen Day 1 Ongoing treatment stable prescription 1 2 csDMARDs Have receive least one biologic disease modify antirheumatic drug ( bDMARD ) treatment RA inadequate response intolerance Previous treatment janus kinase ( JAK ) inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>